Overview

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of skin cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in preventing skin cancer in patients who have previously received treatment for early stage skin cancer.
Phase:
Phase 3
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
National Cancer Institute (NCI)
Treatments:
Eflornithine